Arrowhead Pharmaceuticals, Inc.
58.02USD
-0.3400 (-0.58%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on ARWR.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | -$1.5▼ | -$1.18 | 0 | 5 |
| Next quarter | -$1.37▼ | -$1.35 | 0 | 1 |
| Current year | -$3.51▼ | -$3.08 | 0 | 6 |
| Next year | -$4.98▼ | -$4.57 | 0 | 6 |
Beat in 2 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | -$1.23 | -$1.36 | -0.13 (-10.4%) |
| 2026-03-31 | -$1.11 | -$0.93 | +0.18 (+16.0%) |
| 2025-12-31 | -$0.37 | $0.22 | +0.59 (+159.9%) |
| 2025-09-30 | -$0.16 | -$0.18 | -0.02 (-14.5%) |
190 ratings from 25 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Chardan Capital | Maintained | Buy | $115 | Oct 15, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $120 | Oct 15, 2026 |
| Citigroup | Initiated | Buy | $108 | Sep 8, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $120 | Sep 1, 2026 |
| Chardan Capital | Maintained | Buy | $115 | Aug 31, 2026 |
| RBC Capital | Reiterated | Outperform | $100 | Aug 31, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $115 $120 | Aug 6, 2026 |
| B. Riley Securities | Maintained | Buy | $101 $123 | Jul 30, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $100 $115 | Jul 27, 2026 |
| Morgan Stanley | Maintained | Overweight | $100 $120 | Jul 23, 2026 |
| Piper Sandler | Reiterated | Overweight | $110 $126 | Jul 23, 2026 |
| Chardan Capital | Maintained | Buy | $90 $115 | Jul 22, 2026 |
| JP Morgan | Maintained | Overweight | $88 $95 | Jul 17, 2026 |
| Stifel | Initiated | Buy | $98 | Jul 14, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $100 | Jul 1, 2026 |
| Chardan Capital | Maintained | Buy | $90 | Jun 30, 2026 |
| Leerink Partners | Maintained | Market Perform | $61 $72 | Jun 17, 2026 |
| Bernstein | Maintained | Market Perform | $35 $46 | May 13, 2026 |
| RBC Capital | Maintained | Outperform | $80 $87 | May 8, 2026 |
| JP Morgan | Initiated | Overweight | $88 | May 1, 2026 |
| Morgan Stanley | Upgraded from Equal-Weight | Overweight | $78 $100 | Apr 21, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $100 | Mar 25, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $100 | Feb 10, 2026 |
| B. Riley Securities | Maintained | Buy | $61 $101 | Jan 22, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $85 $100 | Jan 21, 2026 |
66 filings from 14 insiders · 1 buy / 5 sell over 6m
Officers and directors of ARWR, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| OLUKOTUN ADEOYE YDirector | Sell | 2.0k | $86.96 | $174k | Aug 18, 2026 |
| PERRY MICHAEL SDirector | Sell | 11.6k | $87.30 | $1.01M | Aug 18, 2026 |
| COHEN MATTHEW GREGORYDirector | Grant | 11.9k | — | — | Jun 15, 2026 |
| LU HONGBO BDirector | Sell | 3.0k | $76.88 | $228k | May 12, 2026 |
| HAMILTON JAMES COfficer | Sell | 10.0k | $75.00 | $750k | Apr 23, 2026 |
| APEL DANIEL JOSEPHChief Financial Officer | Sell | 13.1k | $70.11 | $934k | Apr 22, 2026 |
| HAMILTON JAMES COfficer | Sell | 10.0k | $64.19 | $642k | Mar 5, 2026 |
| O'BRIEN PATRICK CChief Operating Officer | Grant | 75.0k | — | — | Jan 6, 2026 |
| HAMILTON JAMES COfficer | Grant | 75.0k | — | — | Jan 6, 2026 |
| APEL DANIEL JOSEPHChief Financial Officer | Grant | 75.0k | — | — | Jan 6, 2026 |
| O'BRIEN PATRICK CChief Operating Officer | Gift | 2.5k | — | — | Jan 6, 2026 |
| HAMILTON JAMES COfficer | Sell | 40.2k | $61.24 | $2.53M | Jan 5, 2026 |
| O'BRIEN PATRICK CChief Operating Officer | Sell | 49.5k | $61.12 | $3.12M | Jan 5, 2026 |
| ANZALONE CHRISTOPHER RICHARDChief Executive Officer | Sell | 13.2k | $65.88 | $872k | Jan 2, 2026 |
| O'BRIEN PATRICK CChief Operating Officer | Gift | 2.8k | — | — | Dec 31, 2025 |
| ANZALONE CHRISTOPHER RICHARDChief Executive Officer | Exercise | 51.7k | $6.15 | $318k | Dec 29, 2025 |
| ANZALONE CHRISTOPHER RICHARDChief Executive Officer | Sell | 51.7k | $68.69 | $3.58M | Dec 29, 2025 |
| FERRARI MAURODirector | Sell | 7.5k | $70.00 | $527k | Dec 26, 2025 |
| ANZALONE CHRISTOPHER RICHARDChief Executive Officer | Sell | 26.0k | $66.67 | $1.77M | Dec 22, 2025 |
| OLUKOTUN ADEOYE YDirector | Sell | 10.0k | $66.70 | $677k | Dec 19, 2025 |
No analyst notes on ARWR yet.
Analyst Ratings
14 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 4 | 10 | 1 | 0 | 0 | Buy1.80 |
| 1 mo ago | 4 | 9 | 1 | 0 | 0 | Buy1.79 |
| 2 mo ago | 4 | 8 | 0 | 0 | 0 | Buy1.67 |
| 3 mo ago | 4 | 8 | 0 | 0 | 0 | Buy1.67 |
Members whose judged calls on ARWR have played out most reliably.
No settled calls on ARWR yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice